279 related articles for article (PubMed ID: 34148257)
1. NTRK fusions are extremely rare in bone tumours.
Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
[TBL] [Abstract][Full Text] [Related]
2. Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
Moura MS; Costa J; Velasco V; Kommoss F; Oliva E; Le Loarer F; McCluggage WG; Razack R; Treilleux I; Mills A; Longacre T; Devouassoux-Shisheboran M; Hostein I; Azmani R; Blanchard L; Hartog C; Soubeyran I; Khalifa E; Croce S
Histopathology; 2024 Feb; 84(3):451-462. PubMed ID: 37988282
[TBL] [Abstract][Full Text] [Related]
3. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
[TBL] [Abstract][Full Text] [Related]
4. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
[TBL] [Abstract][Full Text] [Related]
5. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
[No Abstract] [Full Text] [Related]
6. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
7. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
8. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
9. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
[TBL] [Abstract][Full Text] [Related]
10. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
11. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
12. NTRK fusions in osteosarcoma are rare and non-functional events.
Ameline B; Saba KH; Kovac M; Magnusson L; Witt O; Bielack S; Nathrath M; Nord KH; Baumhoer D
J Pathol Clin Res; 2020 Apr; 6(2):107-112. PubMed ID: 32022484
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
[TBL] [Abstract][Full Text] [Related]
15. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
16. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
[TBL] [Abstract][Full Text] [Related]
17. NTRK fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
[TBL] [Abstract][Full Text] [Related]
19. NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China.
Yin L; Shi C; He X; Qiu Y; Chen H; Chen M; Zhang Z; Chen Y; Zhou Y; Zhang H
Pathology; 2023 Apr; 55(3):362-374. PubMed ID: 36641377
[TBL] [Abstract][Full Text] [Related]
20. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]